We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Conditions in the Tumor Microenvironment Change Role of p53

By LabMedica International staff writers
Posted on 09 Aug 2018
Cancer researchers have found that changes occurring in the tumor microenvironment manipulate the activity of fibroblast p53 protein, causing it to promote rather than restrict cancer growth.

Cancer cells coexist with noncancerous adjacent cells that constitute the tumor microenvironment and impact tumor growth through diverse mechanisms. More...
In particular, cancer-associated fibroblasts (CAFs) promote tumor progression in multiple ways. Earlier studies have revealed that in in contrast to the situation in CAFs, p53 in normal fibroblasts (NFs) plays a tumor-suppressive role to restrict tumor growth.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) set out to study the role of p53 in CAFs. To carry out this research, they used a combination of cell culture and a cancer-carrying mouse model.

The investigators reported in the June 19, 2018, issue of the journal Proceedings of the National Academy of Sciences of the United States of America that the transcriptional program supported by p53 was altered substantially in CAFs relative to NFs. In agreement, the secretion of proteins dependent on p53 was also altered in CAFs. This transcriptional rewiring rendered p53 a significant contributor to the distinct intrinsic features of CAFs, as well as promoted tumor cell migration and invasion in culture.

The ability of CAFs to promote tumor growth in mice was greatly compromised by depletion of their endogenous p53. Furthermore, co-cultivation of NFs with cancer cells partially rendered their p53-dependent transcriptome to be more similar to that of CAFs.

The investigators concluded by saying, "Our findings raise the intriguing possibility that tumor progression may entail a nonmutational conversion (“education”) of stromal p53, from tumor suppressive to tumor supportive."

Related Links:
Weizmann Institute of Science


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Platelet Function Analyzer
PL-12
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.